Brought to you by 
MediGene to develop and market Epitome's genital wart drug
16 Feb 2000
Executive Summary
Epitome (licenses and develops drugs, sponsors preclinical research and Phase I and II clinical trials) has licensed exclusive worldwide rights to its PolyphenonE genital warts ointment to MediGene (cancer, cardiovascular disease). MediGene has the right to grant sublicenses to the product, while Epitome receives up-front fees, milestone payments, and royalties.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
MediGene to develop and market Epitome's genital wart drug
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice